PMID- 29779970
OWN - NLM
STAT- MEDLINE
DCOM- 20190911
LR  - 20190911
IS  - 1477-2574 (Electronic)
IS  - 1365-182X (Linking)
VI  - 20
IP  - 9
DP  - 2018 Sep
TI  - Transarterial chemoembolization plus iodine-125 implantation for hepatocellular 
      carcinoma: a systematic review and meta-analysis.
PG  - 795-802
LID - S1365-182X(18)30790-1 [pii]
LID - 10.1016/j.hpb.2018.03.015 [doi]
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is the most common malignancy in 
      liver. Transarterial chemoembolization (TACE) is recommended as an effective 
      treatment in advanced HCC patients. Recent studies showed iodine-125 seed (a 
      low-energy radionuclide) can provide long-term local control and increase 
      survival for HCC patients. The aim of the study was to evaluate the outcome of 
      TACE plus iodine-125 seed in comparison with TACE alone for HCC. METHODS: A 
      comprehensive search of studies among PubMed, Embase, Cochrane Central Register 
      of Controlled Trials, and Cochrane Database of Systematic Reviews was conducted 
      with published date from the earliest to January 10th, 2018. No language 
      restrictions were applied, while only prospective randomized controlled trials 
      (RCTs) or non-randomized controlled trials (non-RCTs) were eligible for a 
      full-text review. The primary outcome was overall survival (OS), response rate 
      (the rate of partial atrophy or complete clearance of the tumor lesion) and 
      adverse events (AEs). The odds ratios (ORs) were combined using either 
      fixed-effects model or random-effects model. All statistical analyses were 
      performed using the Stata 12.0 software. RESULTS: 9 studies were included, 
      involving 894 patients. Among them, 473 patients received combined therapy of 
      TACE plus iodine-125 implantation, compared with 421 patients with TACE alone. 
      Patients receiving combined therapy of TACE plus iodine-125 showed significantly 
      improvement in 1-year OS (OR = 4.47, 95% confidence intervals (CI): 2.97-6.73; 
      P < 0.001), 2-year OS (OR = 4.72, 95% CI: 2.63-8.47; P < 0.001). No significant 
      publication bias was observed in any of the measured outcomes. CONCLUSIONS: Based 
      on these findings, TACE plus iodine-125 implantation achieves better clinical 
      efficacy compared with TACE alone in the treatment of HCC.
CI  - Copyright (c) 2018. Published by Elsevier Ltd.
FAU - Zhu, Ze-Xin
AU  - Zhu ZX
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu, 610041, China.
FAU - Wang, Xiao-Xue
AU  - Wang XX
AD  - Department of Dermatovenereology, West China Hospital, Sichuan University, 
      Chengdu, 610041, China.
FAU - Yuan, Ke-Fei
AU  - Yuan KF
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu, 610041, China. Electronic address: ykf13@163.com.
FAU - Huang, Ji-Wei
AU  - Huang JW
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu, 610041, China. Electronic address: 
      huangjiweimd@foxmail.com.
FAU - Zeng, Yong
AU  - Zeng Y
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu, 610041, China. Electronic address: 
      zengyong@medmail.com.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20180518
PL  - England
TA  - HPB (Oxford)
JT  - HPB : the official journal of the International Hepato Pancreato Biliary 
      Association
JID - 100900921
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Carcinoma, Hepatocellular/mortality/pathology/*therapy
MH  - Chemoembolization, Therapeutic/adverse effects/*methods/mortality
MH  - Chemoradiotherapy/adverse effects/*methods/mortality
MH  - Humans
MH  - Iodine Radioisotopes/*administration & dosage/adverse effects
MH  - Liver Neoplasms/mortality/pathology/*therapy
MH  - Radiopharmaceuticals/*administration & dosage/adverse effects
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2018/05/22 06:00
MHDA- 2019/09/12 06:00
CRDT- 2018/05/22 06:00
PHST- 2018/02/04 00:00 [received]
PHST- 2018/03/17 00:00 [revised]
PHST- 2018/03/28 00:00 [accepted]
PHST- 2018/05/22 06:00 [pubmed]
PHST- 2019/09/12 06:00 [medline]
PHST- 2018/05/22 06:00 [entrez]
AID - S1365-182X(18)30790-1 [pii]
AID - 10.1016/j.hpb.2018.03.015 [doi]
PST - ppublish
SO  - HPB (Oxford). 2018 Sep;20(9):795-802. doi: 10.1016/j.hpb.2018.03.015. Epub 2018 
      May 18.